Spero posts Q1 net loss of $7.2M; tebipenem HBr PDUFA date June 18, 2026

Spero Therapeutics, Inc.

2026-Q1 EPS reported -$0.13 vs consensus -$0.18 ▲ beat (+29.2%)

Net loss of $7.2M ($0.13 diluted EPS) vs $13.9M loss ($0.25 EPS) in Q1 2025.
Total revenue of $0.3M, down from $5.9M in prior-year quarter.
Cash and equivalents of $56.1M as of March 31, 2026; cash runway into 2028.
GSK-led NDA for tebipenem HBr in cUTI under FDA review with PDUFA date June 18, 2026.
R&D expenses fell to $2.9M from $13.6M due to Phase 3 trial completion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.